NCT05814666 2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2 Terminated
Clinical Trials
4 trialsNCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT02417753 2017-05-15
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01839604 2017-03-06
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
AstraZeneca
Phase 1 Completed